Literature DB >> 25754262

Biodistribution of Evans blue in an orthotopic AY-27 rat bladder urothelial cell carcinoma model: implication for the improved diagnosis of non-muscle-invasive bladder cancer (NMIBC) using dye-guided white-light cystoscopy.

Sanne Elsen1, Evelyne Lerut2, Ben Van Cleynenbreugel3, Frank van der Aa3, Hein van Poppel3, Peter A de Witte1.   

Abstract

OBJECTIVES: To investigate the possibility of using Evans blue (EB) as a novel diagnostic tool to detect bladder tumours with white-light (WL) cystoscopy, in this preclinical study we examine the biodistribution of EB in the different layers (urothelium, submucosa, muscle) of a normal rat bladder and a rat bladder bearing a malignant urothelium composed of syngeneic AY-27 tumour cells.
MATERIALS AND METHODS: EB was instilled into both normal as well as tumour-bearing rat bladders. After instillation, bladders were removed and snap frozen in liquid nitrogen. The distribution of EB in the different layers was quantified using fluorescence microscopy. To gain more insight into the mechanism underlying the selective accumulation of EB in tumour tissue, bladder sections were prepared for ultrastructural investigations by means of transmission electron microscopy (TEM). In addition, we also examined the expression of E-cadherin, claudin-1 and desmoglein-1 by immunohistochemistry to study the integrity of the bladder wall, as these molecules are key constituents of adherens junctions, tight junctions and desmosomes, respectively.
RESULTS: In most cases, the accumulation of EB in malignant bladders was substantially higher than in healthy bladders, at least when 1 mm EB instillations were used. In case of a 1 mm EB instillation for 2 h, the EB-associated fluorescence in malignant urothelial tissue was 55-times higher than the fluorescence found in normal urothelium. Ultrastructurally, malignant tissue displayed wider intercellular spaces and a decreased number of cell junction components compared with normal tissue, pointing to defects in the urothelial barrier. There were no differences in the expression of E-cadherin, whereas desmoglein-1 staining was stronger in the membranes of healthy bladder urothelium compared with tumour tissue. Claudin-1 expression was negative in all samples tested.
CONCLUSION: EB is selectively taken up by tumour tissue after intravesical instillations in rats bearing bladder tumours. The lower expression of desmoglein-1 in tumour samples, together with the reduced presence of desmosomes seen with TEM, likely imply that desmosomes play an important role in the ultrastructural differences between healthy rat urothelium and tumour tissue, and secondary to that, to the differential uptake of EB in both tissues. We consider that our findings could be useful for future clinical developments in the field of diagnostics for bladder cancer.
© 2015 The Authors. BJU International © 2015 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Evans blue; non-muscle-invasive bladder cancer; orthotopic animal model; white-light cystoscopy

Mesh:

Substances:

Year:  2015        PMID: 25754262     DOI: 10.1111/bju.13113

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  Bladder cancer: Blue dye used to selectively label bladder tumours in rats.

Authors:  Peter Sidaway
Journal:  Nat Rev Urol       Date:  2015-03-24       Impact factor: 14.432

2.  Evans blue-mediated white-light detection of non-muscle-invasive bladder cancer: A preclinical feasibility and safety study using a rat bladder urothelial cell carcinoma model.

Authors:  Sanne Elsen; Evelyne Lerut; Frank Van Der Aa; Ben Van Cleynenbreugel; Hendrik Van Poppel; Peter De Witte
Journal:  Mol Clin Oncol       Date:  2016-10-04

Review 3.  Evans Blue Dye: A Revisit of Its Applications in Biomedicine.

Authors:  Linpeng Yao; Xing Xue; Peipei Yu; Yicheng Ni; Feng Chen
Journal:  Contrast Media Mol Imaging       Date:  2018-04-22       Impact factor: 3.161

4.  A 7-gene signature predicts the prognosis of patients with bladder cancer.

Authors:  Fucai Tang; Zhibiao Li; Yongchang Lai; Zechao Lu; Hanqi Lei; Chengwu He; Zhaohui He
Journal:  BMC Urol       Date:  2022-01-28       Impact factor: 2.264

Review 5.  Immune status for monitoring and treatment of bladder cancer.

Authors:  Shen Pan; Shijie Li; Yunhong Zhan; Xiaonan Chen; Ming Sun; Xuefeng Liu; Bin Wu; Zhenhua Li; Bitian Liu
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.